Dupixent Lawsuit Dupixent lawsuits are being investigated for patients who developed rare blood cancers such as cutaneous T-cell lymphoma (CTCL) after receiving injections, alleging that Sanofi and Regeneron failed to warn about the potential risks of immune suppression and delayed cancer diagnosis.
Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Truvada Lawsuit Over Failure to Warn About HIV Drug Risks Allowed To Move Forward March 31, 2021 Irvin Jackson Add Your Comments A federal judge has rejected a motion filed by Gilead Sciences, which sought to dismiss a Truvada lawsuit which alleges the company should have used safer active ingredients in its HIV drugs, allowing failure to warn claims to move forward. The decision came in one of a growing number of HIV drug lawsuits filed against Gilead, each raising similar allegations that the active ingredient tenofovir disoproxil fumarate (TDF) in the blockbuster mediations Truvada, Viread, Atripla, Complera and Stribild is excessively toxic and threatens kidneys and bones, yet consumers and the medical community were not adequately warned about the risk. Plaintiffs allege Gilead had already discovered an alternative ingredient, tenofovir alafenamide fumarate (TAF), which is equally as effective at smaller doses, making it less toxic and safer for patients. However, instead of developing and marketing TAF-based HIV drugs, Gilead decided to continue promoting the more toxic TDF drugs until its patent protection ran out, only then ramping up sales and marketing for the TAF versions of the drugs. HIV DRUGS LAWSUITS Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs? Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION HIV DRUGS LAWSUITS Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs? Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The recent ruling came in a case filed Anthony Gaetano, who filed his lawsuit against Gilead in New Jersey state court in July 2020, which was then removed by Gilead (PDF) to federal court just days later. Once it was transferred to the U.S. District Court for the District of New Jersey, Gilead filed a motion to dismiss, arguing that Gaetano’s state law claims over failure to warn about the Truvada risks are preempted by federal law. In an opinion (PDF) issued on March 26, U.S. District Judge Kevin McNulty rejected Gilead’s position and allowed the case to move forward. McNulty pointed out the lawsuit alleges Gilead acquired new information about the side effects of its HIV drugs, which the company did not pass on to federal regulators. “Dismissal is thus appropriate only if it is manifest from the face of the Complaint that the risks Gilead allegedly failed to warn about did not meet the definition of newly acquired information,” McNulty wrote. “This Gilead cannot show, because some of Gaetano’s allegations, interpreted in the light most favorable to him, do seem to concern newly acquired information.” That information, according to the lawsuit, came in the form of Gilead’s own studies, conducted from October 2001 through May 2007, which indicated otherwise healthy individuals were experiencing adverse kidney events while taking Truvada. However, Gilead allegedly failed to warn doctors to monitor patients for kidney problems after this new information became available. It was only after the blockbuster drugs were about to face competition from generic equivalents of Truvada and other TDF drugs that Gilead introduced safer TAF-based versions, marketing them as safer than the toxic drugs they had sold for years without adequate warnings for consumers. Gaetano and other plaintiffs allege the decision to withhold development of TAF-based drugs was part of a scheme intended to allow Gilead to maintain an essential monopoly on HIV treatments until at least 2032. However, as a result of this decision to place profits before consumer safety, thousands of individuals nationwide have been left with severe injuries that may have been avoided. Written by: Irvin Jackson Senior Legal Journalist & Contributing Editor Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends. Tags: Atripla, Complera, Gilead, HIV, HIV Drugs, Kidney Damage, Stribild, Truvada, Viread More HIV Drugs Lawsuit Stories Side Effects of Truvada, Other NRTI Drugs Used To Treat HIV Could Cause Glaucoma: Study July 24, 2025 Gilead Settles HIV Drug Lawsuit Over Patent on Truvada and Descovy January 20, 2025 U.S. Government Files Appeal Over Gilead Truvada, Descovy HIV Drug Patents July 10, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: yesterday) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025) Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: 2 days ago) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025) Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 3 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)
Side Effects of Truvada, Other NRTI Drugs Used To Treat HIV Could Cause Glaucoma: Study July 24, 2025
Wayfair Fire Pit Lawsuit Links Flame Jetting Explosion to Defective Design (Posted: yesterday) In March 2026, a jury is scheduled to hear a Wayfair fire pit lawsuit from a woman who suffered burns to nearly half her body. MORE ABOUT: TABLETOP FIRE PIT LAWSUITAmazon Tabletop Fire Pit Lawsuit Alleges ‘Flame-Jetting’ Caused Third Degree Burns (08/29/2025)Tabletop Fire Pit Burn Victims Share Stories of Explosions and Devastating Injuries (08/21/2025)Colsen Fire Pit Lawsuit Involving Severe Burn Injuries Suffered by a Child Set for Trial Next Year (08/14/2025)
Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (Posted: 2 days ago) Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL). MORE ABOUT: DUPIXENT LAWSUITDupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)
Depo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (Posted: 3 days ago) A new study appears to further confirm and quantify the risks of Depo-Provera meningioma side effects, potentially providing further evidence for growing litigation. MORE ABOUT: DEPO-PROVERA LAWSUITPfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)Experts Weigh In On Depo-Provera Brain Tumor Risks, As Lawsuits Continue to Mount (08/20/2025)